3 Result: Trevena
Pre-Market Movers: Marker Therapeutics Surges on MT-601 Potential, Trevena on Milestone Payment
May 31st, 2023
Marker Therapeutics, Inc. (Nasdaq: MRKR) shared positive pre-clinical data regarding their T cell product candidate, MT-601, which targets multiple tumor-associated antigens (multiTAA) in lymphoma cells, including those resistant to CD19 CAR T cell t. Read more
FREYR Battery and Trevena Surpass Estimates, SoFi Technologies Downgraded, PlayAGS Upgraded
May 15th, 2023
FREYR Battery (NYSE: FREY) has announced its first quarter 2023 financial results, reporting a loss of $0.09 per share. This result surpasses the consensus estimate of a loss of $0.29 per share. Despite the loss, the company's pre-market trading refl. Read more
Trevena and Immuron Make Strides in Medical Advancements with New Approvals and Collaborations, Imperial Petroleum Posts Record Revenues and Profitability, Resulting in a Surge in Stock Prices
May 08th, 2023
Trevena, Inc. (Nasdaq: TRVN) made a significant announcement that its partner in China, Jiangsu Nhwa, has received formal approval from the National Medical Products Administration for OLINVYK, a medication for adults who require intravenous opioid a. Read more
Want To Find Some News?
News By Industries
Recent Post
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025
Member Login